Just when you thought woke in action was a thing of the past — hold your horses! On May 1, public school districts across the state will be closing to allow teachers to attend what is being billed as ...

The Phillies are so committed to running back this team that they’ve fired their manager at midseason again. That worked in 2022. Now they just need a repeat of everything else that went right four ...

More than three years after acquiring Twitter, Elon Musk says he’s nearing his long-stated goal of turning it into an “everything app” with a new financial services tool that he pledged to launch for ...

New York City FC will attempt to snap a four-match winless skid in league play on Wednesday night when they welcome FC Cincinnati to Yankee Stadium. While NYCFC (3-3-2, 11 points) continued their ...

Blake has over a decade of experience writing for the web, with a focus on mobile phones, where he covered the smartphone boom of the 2010s and the broader tech scene. When he's not in front of a ...

To me, "Fade Into You" is not a song that makes sense as a duet. Mazzy Star's 1993 classic is a solitary murmur of sleepy longing. There's obviously a "you" in the song, but I think the "you" exists ...

All YouTube users are getting an option to set their Shorts time limit to zero minutes. All YouTube users are getting an option to set their Shorts time limit to zero minutes. is a news writer ...

My name is Cori Ritchey, and I am an exercise physiology nerd turned fitness journalist, and the fitness editor at Women’s Health. When I’m not writing, editing, and researching fitness, I’m teaching ...

Don't settle for sluggish Wi-Fi. Learn what internet speed tests mean and how to troubleshoot and fix common issues. Joe Supan is a senior writer for CNET covering home technology, broadband, and ...

You’re reading The New Yorker’s daily newsletter, a guide to our top stories, featuring exclusive insights from our writers and editors. Sign up to receive it in your inbox. One of Donald Trump’s ...

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today reported financial results ...